Clinical Trial Update: Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Capmatinib with Spartalizumab or placebo in advanced MET exon 14 skipping NSCLC was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2024-02-06